Cancer-Associated Venous Thromboembolic Disease

Appropriate risk stratification, prophylaxis, and treatment of cancer-associated VTE is critical to improving the outcomes of patients with this common and life-threatening condition. Clinicians should be knowledgeable in factors that enhance VTE risk and should understand appropriate prophylaxis regimens for high-risk patients. Additionally, clinicians should be educated on the evaluation of the diverse subtypes of VTE and the use of therapeutic anticoagulation agents as well as the risks associated with their use.

Target Audience

This program is designed to meet the educational needs of physicians, nurses, PAs, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Integrate current prophylactic treatment regimens into clinical practice in patients with cancer that are at high risk of developing VTE.
  • Evaluate the diverse types of VTE that may develop in patients with malignancy.
  • Discuss therapeutic anticoagulation options and potential contraindications as well as risks associated with their use.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Taiho Oncology, Inc.
  • Revolution Medicines

Supported by an independent educational grant from Daiichi Sankyo.

This educational activity is supported by an independent medical education grant from GSK. 

Course summary
Available credit: 
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
06/15/2026
Course expires: 
03/01/2027
Part of: 
Recorded Presentations from the NCCN 2026 Oncology Fellows Program: New Horizons in Quality Cancer Care™
Michael B. Streiff, MD
Johns Hopkins Kimmel Cancer Center
 
NCCN Continuing Education Disclosure Policy
 
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery. Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated. 

Michael B. Streiff, MD
CSL Bhering: Consulting Fee; Scientific Advisor 
Genentech, Inc.: Grant/Research Support
Grifols, S.A.: Grant/Research Support
Regeneron Pharmaceuticals, Inc.: Grant/Research Support 

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians: NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: NCCN designates this educational activity for a maximum of 0.75 contact hour.

Pharmacists: NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-26-047-H01-P

PAs: NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until March 1, 2027. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: 

  • A device with an Internet connection and sound playback capability (speakers or a headset) 
  • Adobe Reader or other PDF reader software for certificate viewing/printing